Related references
Note: Only part of the references are listed.Amlodipine Increased Endothelial Nitric Oxide and Decreased Nitroxidative Stress Disproportionately to Blood Pressure Changes
R. Preston Mason et al.
AMERICAN JOURNAL OF HYPERTENSION (2014)
Endocan-A Novel Inflammatory Indicator in Newly Diagnosed Patients With Hypertension: A Pilot Study
Sevket Balta et al.
ANGIOLOGY (2014)
Endocan Elicits Severe Vascular Inflammatory Responses In Vitro and In Vivo
Wonhwa Lee et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2014)
Serum endocan levels as a marker of disease activity in patients with Behcet disease
Ilknur Balta et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
2013 ESH/ESC Guidelines for the management of arterial hypertension
Giuseppe Mancia et al.
BLOOD PRESSURE (2013)
Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease
I. Balta et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
The Effects of Arterial Blood Pressure Reduction on Endocan and Soluble Endothelial Cell Adhesion Molecules (CAMs) and CAMs Ligands Expression in Hypertensive Patients on Ca-Channel Blocker Therapy
Refmir Tadzic et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2013)
Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the Meantime, Some Challenges and Recommendations
Seth S. Martin et al.
AMERICAN JOURNAL OF CARDIOLOGY (2012)
The cardiovascular continuum refined: A hypothesis
Massimo Volpe et al.
BLOOD PRESSURE (2010)
Valsartan Improves Endothelial Dysfunction in Hypertension: A Randomized, Double-Blind Study
Nikolaos Tzemos et al.
CARDIOVASCULAR THERAPEUTICS (2009)
Amlodipine improves endothelial function and metabolic parameters in patients with hypertension
Kwang Kon Koh et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2009)
Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension
Yoshitaka Hirooka et al.
CLINICAL AND EXPERIMENTAL HYPERTENSION (2008)
Blood pressure, C-reactive protein, and risk of future cardiovascular events
GJ Blake et al.
CIRCULATION (2003)
New markers of inflammation and endothelial cell activation - Part I
PE Szmitko et al.
CIRCULATION (2003)
The clinical implications of endothelial dysfunction
ME Widlansky et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients
KK Koh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1
D Béchard et al.
JOURNAL OF IMMUNOLOGY (2001)
Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension
S Taddei et al.
HYPERTENSION (2001)
Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms
R Berkels et al.
HYPERTENSION (2001)
Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies
D Bechard et al.
JOURNAL OF VASCULAR RESEARCH (2000)
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
PM Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
